Skip to main content
MediPharm Labs Corp. logo

MediPharm Labs Corp. — Investor Relations & Filings

Ticker · LABS LEI · 875500SIGS9KXW34K754 TSX Manufacturing
Open in API
Filings indexed 274 across all filing types
Latest filing 2026-04-27 Regulatory Filings
Country CA Canada
Listing TSX LABS

About MediPharm Labs Corp.

https://medipharmlabs.com/

MediPharm Labs Corp. is a full-service pharmaceutical company specializing in the development, formulation, processing, packaging, and distribution of precision-based, advanced cannabinoid products. Operating from Good Manufacturing Practices (GMP) certified facilities, the company focuses on producing pharma-quality cannabis Active Pharmaceutical Ingredients (API), concentrates, and derivative products. Utilizing strict manufacturing standards and ISO standard cleanrooms, MediPharm Labs ensures its offerings are pure, trusted, and precisely dosable for patients and consumers. Services include wholesale and white label platforms for domestic and international clients. The company holds a Pharmaceutical Drug Establishment License, enabling the manufacture of pharmaceutical drugs containing cannabis.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date (amended) - English.pdf
Regulatory Filings Classification · 1% confidence The document is a TSX Trust Company letter confirming that Medipharm Labs Corp.'s Notice of Record and Meeting Dates was delivered to the Canadian Depository, and it provides administrative meeting logistics (meeting date, record date, classes of securities, Notice-and-Access details). It does not contain financial results, proxy materials themselves, or an AGM presentation, nor does it announce dividends or share transactions. It is a regulatory communication that doesn’t fit any more specific category, so it falls under the fallback category “Regulatory Filings (RNS).”
2026-04-27 English
Notice of the meeting and record date - English.pdf
Board/Management Information Classification · 1% confidence The document is a press release announcing the resignation of the prior CFO and the appointment of a new CFO (senior management change). There are no financial statements or detailed reporting beyond management change, and it clearly falls under announcements of board or senior management changes.
2026-04-11 English
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a TSX Trust Company notice confirming the record date and meeting date for the upcoming Annual Meeting of Security Holders, including proxy-related details (Notice-and-Access, delivery to beneficial holders, proxy materials). It is administrative proxy solicitation information rather than full financial results, an annual report, or a standalone legal filing. This falls under Proxy Solicitation & Information Statement (materials sent to shareholders to provide information and request votes).
2026-04-11 English
Notice of the meeting and record date - English.pdf
Board/Management Information Classification · 1% confidence The document is a corporate press release announcing the resignation of the current CFO and the appointment of a new Chief Financial Officer. It specifically details changes in senior management roles. This aligns with the definition for Board/Management Information (MANG).
2026-04-11 English
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a confirmation from TSX Trust Company regarding the dispatch of the Notice of Record and Meeting Dates for the upcoming Annual Meeting of Security Holders, including proxy distribution details (Notice-and-Access, beneficial holders, etc.). This is part of the proxy solicitation/information statement process—not the full proxy statement itself, but clearly falls under materials sent to shareholders to inform and solicit their votes. Therefore, it aligns with the Proxy Solicitation & Information Statement category (PSI) rather than a general regulatory filing or a results announcement.
2026-04-11 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release announcing MediPharm Labs’ full year and fourth quarter 2025 financial results, summarizing key revenue, EBITDA figures, cash position, and providing conference call details. It is not the full annual report or a quarterly regulatory filing, but an earnings announcement. Therefore, it matches the Earnings Release category. FY 2025
2026-03-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.